NILK 2301
Alternative Names: NI-2301; NILK-2301Latest Information Update: 26 Apr 2024
At a glance
- Originator NovImmune SA
- Developer Light Chain Bioscience
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Mar 2024 Phase-I clinical trials in Solid tumours (Parenteral) in the first quarter of 2024 (Light Chain Bioscience pipeline, April 2024)
- 14 Apr 2023 Adverse events and pharmacodynamics data from preclinical studies in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 09 Sep 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)